Fluperlapine in 104 schizophrenic patients. Open multicenter trial.

摘要: Twelve parallel, open, uncontrolled therapeutic studies on 3-fluoro-6-(4-methyl-piperazinyl)- 11H -dibenz[b,e]azepine ( fluperlapine , NB-106 689) were performed as a multicenter trial using standardized protocol/case report forms and inclusion global assessment criteria. 66% of 104 medium to severe acute or relapsed schizophrenic patients showed very good overall benefit (responder rate 80%) with 200-400 mg daily, median 300; 20-1200 mg; 6 weeks. Ratings FSCL -NL = (Fischer Symptom Check List Neuroleptics, BPRS Brief Psychiatric Rating Scale, FSUCL Fischer Somatic Symptoms Untoward Effects List) quick onset action (25% improvement in 5 days) all important secondary single symptoms symptom groups. highly correlated (R 0.87). Tolerability was 88% (very 65%, poor bad 12%), mild moderate fatigue being the most prominent untoward effect (means 25% patients, max. 31 per control) followed by dizziness, tremor, dry mouth (10%). No drug-induced Parkinsonism seen. recurrent relevant abnormalities relation observed safety data (circulation, blood, kidney liver function). Several times paroxysmal dysrhythmias/sharp waves seen EEG, our 2 experienced epileptiform seizures short duration after overdosage. In one patient showing granulocytopenia before starting an agranulocytosis seen, which normalized quickly stopping .